Neurology: Volume 95, Number 13, September 29, 2020 Exam #1 - Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

About this course

  • Released: 09/29/2020
  • Expires: 09/29/2023

FIVE YEARS OF OCRELIZUMAB IN RELAPSING MULTIPLE SCLEROSIS: OPERA STUDIES OPEN-LABEL EXTENSION

LEARNING OBJECTIVES:

Upon completion of the article by Hauser et al., the participant should be able to:

  • Discuss the clinical efficacy—as measured by annualized relapse rate—of continuous ocrelizumab therapy versus two years of interferon followed by ocrelizumab therapy in this study of patients with relapsing multiple sclerosis (MS)

  • State the proportion of patients who received continuous ocrelizumab therapy who were found to have no evidence of disease activity during the open label extension period of this study

  • Describe various safety outcomes seen among patients with relapsing MS treated with continuous ocrelizumab therapy versus two years of interferon followed by ocrelizumab in this study

CORE COMPETENCIES:

The article by Hauser et al. covers the following core competency:

  • Medical Knowledge

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

James WM Owens Jr. MD, PhD receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology. Adam Kelly, MD, has served as a guest editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME